BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

767 related articles for article (PubMed ID: 21624500)

  • 1. FDA-approved drug labeling for the study of drug-induced liver injury.
    Chen M; Vijay V; Shi Q; Liu Z; Fang H; Tong W
    Drug Discov Today; 2011 Aug; 16(15-16):697-703. PubMed ID: 21624500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative structure-activity relationship models for predicting drug-induced liver injury based on FDA-approved drug labeling annotation and using a large collection of drugs.
    Chen M; Hong H; Fang H; Kelly R; Zhou G; Borlak J; Tong W
    Toxicol Sci; 2013 Nov; 136(1):242-9. PubMed ID: 23997115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury.
    Chen M; Borlak J; Tong W
    Hepatology; 2013 Jul; 58(1):388-96. PubMed ID: 23258593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver safety assessment: required data elements and best practices for data collection and standardization in clinical trials.
    Avigan MI; Bjornsson ES; Pasanen M; Cooper C; Andrade RJ; Watkins PB; Lewis JH; Merz M
    Drug Saf; 2014 Nov; 37 Suppl 1(Suppl 1):S19-31. PubMed ID: 25352325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatotoxicity by Drugs: The Most Common Implicated Agents.
    Björnsson ES
    Int J Mol Sci; 2016 Feb; 17(2):224. PubMed ID: 26861310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Liver Toxicity Knowledge Base (LKTB) and drug-induced liver injury (DILI) classification for assessment of human liver injury.
    Thakkar S; Chen M; Fang H; Liu Z; Roberts R; Tong W
    Expert Rev Gastroenterol Hepatol; 2018 Jan; 12(1):31-38. PubMed ID: 28931315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a Battery of
    Rathman J; Yang C; Ribeiro JV; Mostrag A; Thakkar S; Tong W; Hobocienski B; Sacher O; Magdziarz T; Bienfait B
    Chem Res Toxicol; 2021 Feb; 34(2):601-615. PubMed ID: 33356149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of Decision Forest Models for Prediction of Drug-Induced Liver Injury in Humans Using A Large Set of FDA-approved Drugs.
    Hong H; Thakkar S; Chen M; Tong W
    Sci Rep; 2017 Dec; 7(1):17311. PubMed ID: 29229971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-induced liver injury and drug development: industry perspective.
    Regev A
    Semin Liver Dis; 2014 May; 34(2):227-39. PubMed ID: 24879986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-induced liver injury.
    Holt M; Ju C
    Handb Exp Pharmacol; 2010; (196):3-27. PubMed ID: 20020257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-induced liver injury severity and toxicity (DILIst): binary classification of 1279 drugs by human hepatotoxicity.
    Thakkar S; Li T; Liu Z; Wu L; Roberts R; Tong W
    Drug Discov Today; 2020 Jan; 25(1):201-208. PubMed ID: 31669330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety data and withdrawal of hepatotoxic drugs.
    Babai S; Auclert L; Le-Louët H
    Therapie; 2021; 76(6):715-723. PubMed ID: 29609830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of average molecular weight (AMW) as a useful chemical descriptor to discriminate liver injury-inducing drugs.
    Shimizu Y; Sasaki T; Takeshita JI; Watanabe M; Shizu R; Hosaka T; Yoshinari K
    PLoS One; 2021; 16(6):e0253855. PubMed ID: 34170966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case definition and phenotype standardization in drug-induced liver injury.
    Aithal GP; Watkins PB; Andrade RJ; Larrey D; Molokhia M; Takikawa H; Hunt CM; Wilke RA; Avigan M; Kaplowitz N; Bjornsson E; Daly AK
    Clin Pharmacol Ther; 2011 Jun; 89(6):806-15. PubMed ID: 21544079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals.
    Lammert C; Einarsson S; Saha C; Niklasson A; Bjornsson E; Chalasani N
    Hepatology; 2008 Jun; 47(6):2003-9. PubMed ID: 18454504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measures of BSEP Inhibition In Vitro Are Not Useful Predictors of DILI.
    Chan R; Benet LZ
    Toxicol Sci; 2018 Apr; 162(2):499-508. PubMed ID: 29272540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A high content screening assay to predict human drug-induced liver injury during drug discovery.
    Persson M; Løye AF; Mow T; Hornberg JJ
    J Pharmacol Toxicol Methods; 2013; 68(3):302-13. PubMed ID: 23933113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting and preventing acute drug-induced liver injury: what's new in 2010?
    Liss G; Rattan S; Lewis JH
    Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1047-61. PubMed ID: 20615079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Approaches to the study of drug-induced liver injury.
    Fontana RJ
    Clin Pharmacol Ther; 2010 Sep; 88(3):416-9. PubMed ID: 20664536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Silico Prediction of Drug-Induced Liver Injury Based on Ensemble Classifier Method.
    Wang Y; Xiao Q; Chen P; Wang B
    Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31443562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.